Literature DB >> 8633840

Rheumatoid arthritis: treat now, not later!

M E Weinblatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8633840     DOI： 10.7326/0003-4819-124-8-199604150-00012

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  14 in total

1.  The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.

Authors:  Mathilde Benhamou; Nathalie Rincheval; Carine Roy; Violaine Foltz; Sylvie Rozenberg; Jean Sibilia; Thierry Schaeverbeke; Pierre Bourgeois; Philippe Ravaud; Bruno Fautrel
Journal:  J Rheumatol       Date:  2009-03-13       Impact factor: 4.666

2.  Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension.

Authors:  T K Kvien; H K Zeidler; P Hannonen; F A Wollheim; O Førre; I Hafström; J P Kaltwasser; M Leirisalo-Repo; B Manger; L Laasonen; H Prestele; P Kurki
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  Etanercept: a review of its use in rheumatoid arthritis.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

4.  Therapeutic effect of dimethyl dimethoxy biphenyl dicarboxylate on collagen-induced arthritis in rats.

Authors:  Roba M Talaat; Amira S Abo-El-Atta; Sabah M Farou; Karima I El-Dosoky
Journal:  Chin J Integr Med       Date:  2014-03-02       Impact factor: 1.978

Review 5.  Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.

Authors:  Mahboob U Rahman; Jacqui Buchanan; Mittie K Doyle; Elizabeth C Hsia; Timothy Gathany; Shreekant Parasuraman; Daniel Aletaha; Eric L Matteson; Philip G Conaghan; Edward Keystone; Désireé van der Heijde; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2011-06-27       Impact factor: 19.103

6.  The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.

Authors:  Nuria C Navarro Coy; Sarah Brown; Ailsa Bosworth; Claire T Davies; Paul Emery; Colin C Everett; Catherine Fernandez; Janine C Gray; Suzanne Hartley; Claire Hulme; Anne-Maree Keenan; Christopher McCabe; Anthony Redmond; Catherine Reynolds; David Scott; Linda D Sharples; Sue Pavitt; Maya H Buch
Journal:  BMC Musculoskelet Disord       Date:  2014-12-23       Impact factor: 2.362

7.  Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure.

Authors:  Luis Arturo Gutierrez-Gonzalez; Marco Antonio Rivera Gudiño; Ibell Oropeza Ceija; Marialina Marin Leonet; Zair Tovar Noguera
Journal:  Open Rheumatol J       Date:  2013-10-18

8.  Rheumatoid arthritis: travelling biological era a Romanian X-ray population.

Authors:  Corina Mogosan; V Stoica; Carmen Mihai; L Macovei; I Ancuta; Claudia Ciofu; Fulvia Stefanescu; M Bojinca; A Martin; Mihaela Milicescu; Viorica Crisan; Mioara Banciu; St Suteanu
Journal:  J Med Life       Date:  2009 Oct-Dec

9.  Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.

Authors:  T Sokka; T Pincus
Journal:  Rheumatology (Oxford)       Date:  2008-08-07       Impact factor: 7.580

10.  Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice.

Authors:  David J Shealy; Paul H Wooley; Eva Emmell; Amy Volk; Amy Rosenberg; George Treacy; Carrie L Wagner; Lois Mayton; Don E Griswold; Xiao-Yu R Song
Journal:  Arthritis Res       Date:  2002-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.